Showing results (131-140 of 682) with videos related to
Sort By:
Pageof 69
Critical Reviews in Oncology/Hematology|July 13, 2016
Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?Aziz Nazha, Joseph D Khoury, Srdan Verstovsek, et al.Nature Reviews. Drug Discovery|February 2, 2011
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyondAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes, et al.Leukemia Research|January 5, 2010
Mycotic pulmonary artery aneurysm due to Aspergillus infection in a patient with leukemia: case report and review of the literatureMatjaz Sever, Srdan Verstovsek, Jeremy Erasmus, et al.Annals of Hematology|March 21, 2018
Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemiaMaliha Khan, Tariq Muzzafar, Hagop Kantarjian, et al.American Journal of Clinical Pathology|January 23, 2010
Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosisBo Feng, Srdan Verstovsek, Jeffrey L Jorgensen, et al.Expert Opinion on Investigational Drugs|November 17, 2006
Experimental therapy in myelofibrosis with myeloid metaplasiaSrdan Verstovsek, Alfonso Quintás-Cardama, Hagop Kantarjian, et al.Therapeutic Advances in Hematology|August 15, 2022
Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerationsAlexandra R Lovell, Nadya Jammal, Prithviraj BoseExpert Review of Hematology|December 14, 2025
Current treatments, practical management, and emerging investigational therapies for myelofibrosisSrinivas Tantravahi, Firas El Chaer, Prithviraj BoseCurrent Treatment Options in Oncology|March 14, 2017
Treatment of Relapsed/Refractory Acute Myeloid LeukemiaPrithviraj Bose, Pankit Vachhani, Jorge E CortesExpert Opinion on Investigational Drugs|May 8, 2013
Cyclin-dependent kinase inhibitor therapy for hematologic malignanciesPrithviraj Bose, Gary L Simmons, Steven GrantPageof 69